Exclusive Summary

• • A Potential Best-in-class STAT6 degrader.
• • In vitro activity reaches the picomolar (pM) level, significantly outperforming dupilumab.
• • Favorable oral exposure across various animal species.
• • Excellent degradation activity in animal models (in vivo).
• • Wide range of indications with huge MKT potential: AD,COPD, EoE etc.

Asset Materials

Contact Us for Full Materials